|Unit Price:||USD 1.0000 / Kilogram |
|Min. Order:||1 Kilogram|
|Delivery Time:||15 Days|
Model No.: 870281-82-6
Packaging: As Quantity
Productivity: As Order
Place of Origin: CHINA
The highly advanced and finely formulated Idelalisib(CAL-101) CAS 870281-82-6 we offer our customers are of popular brands known for consistently high quality. Idelalisib(CAL-101) CAS NO 870281-82-6 belongs to Phosphoinositide 3-kinase inhibitor. It always used to treat Chronic lymphocytic leukemia, Follicular B-cell non-Hodgkin lymphoma and Small lymphocytic lymphoma. Our Idelalisib(CAL-101) 870281-82-6 is safe, reliable and effective. Please contact us!
Cas No.: 870281-82-6
Synonyms: CAL-101;GS1101;CAL-101 (GS-1101);5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone;CAL101,CAL 101;CAL-101;CAL-101 (Idelalisib, GS-1101);(S)-2-(1-((9H-Purin-6-yl)aMino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one;Idelalisib(CAL-101)
Packing: Export worthy packing
Material Safety Data Sheet:Available on request
CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
IC50 value: 2.5 nM 
in vitro: CAL-101 is not sensitive to other PI3K class I subunits including p110α, p110β, and p110γ. CAL-101 specifically blocks Fc?R1 p110δ-mediated CD63 expression with an EC50 of 8 nM in primary basophil. CAL-101 exhibits greater activity in B-cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia (CLL) cells compared with acute myeloid leukemia (AML) and myeloproliferative neoplasm (MPN) cells. CAL-101 produces the reduction in pAktS473, pAktT308, and the downstream target S6 in SU-DHL-5, KARPAS-422 and CCRF-SB cells with EC50 of 0.1 to 1.0 μM . CAL-101 induces selective cytotoxicity in CLL cells independent of IgVH mutational status or interphase cytogenetics, primarily through a caspase-dependent mechanism. CAL-101 induces cytotoxicity preferentially to CLL cells compared with normal B cells, without producing cytotoxicity in other hematopoietic cells, compared to LY294002. CAL-101 lacks direct cytotoxic potential to T cells and nature killer (NK) cells. CAL-101 can inhibit production of inflammatory cytokines, such as IL-6, IL-10, TNF-α, and IFN-γ, and activation-induced cytokines, such as CD40L. CAL-101 also antagonizes CD40L-mediated CLL cell survival . AL-101 induces an accumulation of cells in G1 and a decrease in the S-phase population in L1236 and L591 cells, which indicates CAL-101 as a novel strategy for the treatment of hodgkin lymphoma (HL) .
We are availabe for several related Intermediates
1) CAS 385-02-4,2-Fluoro-6-nitrobenzoic acid
2) CAS 870281-83-7,2-Fluoro-6-nitro-N-phenylbenzamide
3) CAS 870281-84-8,(S)-([1-(2-fluoro-6-nitro-benzoyl)-phenyl-aMinocarbonyl]-propyl)-carbaMic acid tert-butyl ester
4) CAS 870281-85-9,(S)-tert-butyl (1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbaMate
5) CAS 870281-86-0,(S)-2-(1-aMinopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
6) CAS 870281-82-6,CAL-101
7) CAS 767-69-1,6-Bromopurine
8) N,N'-Bis-(2-Chloroethyl)urea CAS 2214-72-4